Dec 08, 2025, 21:02 ET Beyond the previously reported efficacy data presented at the ESMO 2025 Presidential Symposium and simultaneously published in The Lancet, this presentation further disclosed patient-reported quality of life outcomes based on the EORTC QLQ-C30 questionnaire. Across the immuno-oncology landscape, ivonescimab…
Tune in for the latest research and perspectives on kidney health from NKF. Answer a few questions and we will provide you with information about your kidney health. Learn about the basics of kidney disease, how it is measured, and…
Lakewood-Amedex Biotherapeutics Inc. announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated... announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu…
Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3, in infected diabetic foot ulcers Lakewood-Amedex... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3 Published on 05/18/2026 at 09:38 am…
Lakewood-Amedex Biotherapeutics Inc. announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly... announced positive data for its lead compound, Nu-3, as it advances…
Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3 Published on…
Lakewood-Amedex Biotherapeutics Inc. announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial. Nu-3 is a gel... announced robust preclinical safety data that establishes a strong foundation for clinical dose…
“Together, these milestones mark another significant step forward in the company’s clinical development strategy to address the urgent medical need for new treatments for drug-resistant wound...
Bristol-Myers Squibb (NYSE:BMY) and BioNTech reported positive Phase 2 data for pumitamig in metastatic non-small cell lung cancer. The bispecific immunomodulator pumitamig, targeting PD-L1 and VEGF-A, showed strong antitumor activity with a manageable safety profile. This first global data set…
The FDA has approved Alfasigma's primary biliary cholangitis (PBC) therapy linerixibat, just days after the company licensed it from GSK in a deal worth up to $690 million. The US regulator confirmed approval of IBAT inhibitor linerixibat, under the Lynavoy trade…
Trial design, systematic reviews, medical statistics, and guideline updates.
An article joins this feed when it matches these terms. Each one is also a search of its own.